Anti-Human CD106 (VCAM1) (Clone EB0140E) – Purified No Carrier Protein

VCAM1 synthetic peptide TQIDSPLSGK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0140E-2H1-H2/K2 activity is directed against human VCAM1 and targets peptide sequence TQIDSPLSGK.

VCAM1 (CD106) is an endothelial cell surface glycoprotein involved in inflammatory responses and is responsible for leukocyte adhesion and migration¹. In response to inflammation, VCAM1 is upregulated on endothelial surfaces by TNFα, and ligands binding to VCAM1 initiate a signaling cascade that results in the relaxation of junction adhesion molecules within endothelial cell junctions, leading to leukocyte transendothelial migration. VCAM1 expression is activated by pro-inflammatory cytokines, ROS, high glucose levels, shear stress, and oxidized low-density lipoprotein.

VCAM1 dysregulation plays a role in tumor angiogenesis and metastasis, immunological and inflammatory disorders, including rheumatoid arthritis and asthma¹, as well as cardiovascular disease². Additionally, VCAM1 upregulation is observed on endothelium of grafted organs during rejection. As such, VCAM1 is a target of immunotherapies for various pathologies. VCAM1 has also been proposed as a biomarker for mortality and morbidity for chronic heart failure, coronary artery disease, and arrhythmias since soluble VCAM1 levels increase in patients with cardiovascular disease².

EB0140E-2H1-H2/K2 was generated in rabbit using a non-modified, synthetic peptide sequence (TQIDSPLSGK) from human VCAM1 and was developed for use in immuno-MRM assays³. EB0140E-2H1-H2/K2 did not detect VCAM1 in immunohistochemistry applications evaluated by the Human Protein Atlas, but did detect VCAM1 on a tissue micro-array core of ovarian cancer⁴. Western blotting can detect recombinant VCAM1 protein as well as VCAM1 in cell lysates.